Ibrutinib plus Obinutuzumab as Frontline Therapy for Chronic Lymphocytic Leukemia Is Associated with a Lower Rate of Infusion-Related Reactions and with Sustained Remissions after Ibrutinib Discontinuation: A Single-Arm, Open-Label, Phase 1b/2 Clinical Trial NCT0231576

Ibrutinib-based therapies are costly and require continuous administration. We hypothesized combining BTK inhibition with anti-CD20 monoclonal antibodies would yield deep remissions allowing discontinuation. We enrolled 32 therapy-naïve CLL patients to receive ibrutinib plus obinutuzumab, followed b...

Descripción completa

Detalles Bibliográficos
Autores principales: Castro, Januario E., Lengerke-Diaz, Paula A., Velez Lujan, Juliana, Choi, Michael Y., Moreno-Cortes, Eider F., Forero, Jose V., Garcia-Robledo, Juan Esteban, Jacobs, Chaja, McCarthy, Colin, Heinen, Alaina, Amaya-Chanaga, Carlos I., Kipps, Thomas J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800600/
https://www.ncbi.nlm.nih.gov/pubmed/35103064
http://dx.doi.org/10.1155/2022/4450824

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800600/
https://www.ncbi.nlm.nih.gov/pubmed/35103064
http://dx.doi.org/10.1155/2022/4450824

Ejemplares similares